保肝药在急性髓系白血病初次化疗中肝损伤预防作用的临床观察

发布时间：2019-05-19 15:55

【摘要】：目的探究保肝药在急性髓系白血病(AML)患者化疗中预防肝损伤发生的临床意义。方法回顾性分析某三甲医院血液科2012年1月至2015年12月接受IA方案治疗的128例初诊AML患者使用肝病辅助治疗药(保肝药)预防肝损伤发生的情况。128例病例中使用保肝药物预防的试验组99例,未使用保肝药物预防的对照组29例,试验组又包含谷胱甘肽预防组、异甘草酸镁预防组、谷胱甘肽合并异甘草酸镁预防组以及其他组。试验组在初次诱导化疗的同时使用保肝药物;对照组仅接受化疗,并记录两组患者化疗前后的肝功能生化指标。结果试验组肝损伤发生率和对照组相比无显著性差异(P0.05),三组保肝药之间的预防效果无显著性差异(P0.05),经Cox回归对肝损伤发生的相关因素分析,无显著性差异(P0.05)。结论预防性使用保肝药物并未减少接受IA方案化疗的初治AML患者的肝损伤的发生。
[Abstract]:Objective to investigate the clinical significance of hepatoprotective drugs in preventing liver injury in patients with acute myeloid leukemia (AML). Methods A retrospective analysis was made on the prevention of liver injury in 128 newly diagnosed AML patients treated with IA regimen from January 2012 to December 2015 in the Department of Hematology, a third grade A hospital. 99 patients in the experimental group were prevented with hepatoprotective drugs. There were 29 patients in the control group who did not use hepatoprotective drugs. The experimental group included glutathione prevention group, magnesium isoglycyrrhizinate prevention group, glutathion combined with magnesium isoglycyrrhizinate prevention group and other groups. The experimental group was treated with hepatoprotective drugs at the same time as the first induction chemotherapy, while the control group was only treated with chemotherapy, and the biochemical indexes of liver function before and after chemotherapy were recorded. Results there was no significant difference in the incidence of liver injury between the experimental group and the control group (P 0.05). There was no significant difference in the preventive effect among the three groups (P 0.05). The related factors of liver injury were analyzed by Cox regression. There was no significant difference (P 0.05). Conclusion Preventive use of hepatoprotective drugs does not reduce the incidence of liver injury in patients with AML who receive IA regimen chemotherapy.
【作者单位】：北京大学人民医院药剂科;北京大学药学院药事管理与临床药学系;北京大学人民医院血液科;
【分类号】：R733.71

【相似文献】